TerrAscend stock fell 1.33 percent as New Jersey deal closed
Published on 10/07/2026 at 04:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTerrAscend stock (ISIN CA88105E1088) was last at CAD 0.74 on the Toronto Stock Exchange on October 6, 2026, down 1.33 percent from the prior session. The company closed its Aunt Mary's transaction on September 16, adding a fifth New Jersey dispensary and a retail asset generating more than USD 10 million in annualized revenue, according to GlobeNewswire.
New Jersey footprint expands
The transaction carries total consideration of USD 9 million. The structure includes a USD 3 million five-year unsecured convertible debenture bearing 6.0 percent interest for an option to purchase 35 percent of Aunt Mary's, plus USD 6 million payable if the option is exercised, according to GlobeNewswire. Upon exercise and satisfaction of additional conditions, the company would fully consolidate the business and reach 21 dispensaries across five U.S. states and Canada.
For investors, the important distinction is between the immediate operating contribution and the future consolidation option. The release describes the transaction as immediately accretive to EBITDA and free cash flow, while full consolidation depends on the option and additional conditions.
Q2 revenue returned to growth
TerrAscend reported USD 67.1 million of second-quarter 2026 revenue, up 3.3 percent from the year-earlier quarter. First-half revenue from continuing operations reached USD 132.7 million, compared with USD 129.3 million a year earlier, a 2.6 percent increase, according to TradingView.
Gross margin reached 54.0 percent in Q2, up 290 basis points year over year, while adjusted EBITDA margin rose 170 basis points to 26.3 percent. Adjusted EBITDA was USD 17.7 million, and free cash flow was USD 5.7 million, giving the retail expansion a stronger financial backdrop than revenue growth alone suggests.
Management also targeted 25-26 percent adjusted EBITDA margins and 52-54 percent gross margins for the remainder of 2026, while forecasting 2-3 percent year-over-year revenue growth for Q3, as reported by Zacks. Pricing pressure, inventory and competition remain the main operating variables.
Consensus stays constructive
A September 2026 consensus overview listed 9 analysts, including 8 Buy ratings and 1 Hold rating, with a median price target of USD 1.46, according to Eulerpool. Because the consensus is stated in USD while the Toronto quote is in CAD, the two figures are not used for a direct percentage comparison.
Stock remains below yearly high
At CAD 0.74 on October 6, TerrAscend stock stood 63.0 percent below its 52-week high of CAD 2.00 and 39.6 percent above its 52-week low of CAD 0.53. Market capitalization was CAD 228.8 million, with 73,531 shares traded during the session.
TerrAscend stock facts
- Company: TerrAscend Corp.
- ISIN: CA88105E1088
- Ticker: TSND
- Trading venue: Toronto Stock Exchange
- Price (as of October 6, 2026, 3:59 p.m. ET): CAD 0.74
- Market capitalization: CAD 228.8 million (as of October 6, 2026)
- 52-week range: CAD 0.53-2.00 (as of October 6, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
